These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 16172175

  • 1. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [Abstract] [Full Text] [Related]

  • 2. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 3. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 4. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U, Heinemann V, Wilmanns W.
    Anticancer Res; 1989 Nov; 9(1):119-24. PubMed ID: 2705739
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA, Children's Cancer Group Study 2951.
    J Clin Oncol; 2003 Aug 01; 21(15):2940-7. PubMed ID: 12885813
    [Abstract] [Full Text] [Related]

  • 6. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H.
    Haematologica; 2005 Dec 01; 90(12):1701-3. PubMed ID: 16330449
    [Abstract] [Full Text] [Related]

  • 7. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Lee SS, Lee JH, Lee JH, Kim DY, Kim SH, Lim SN, Lee YS, Seol M, Ryu SG, Kang YA, Jang S, Park CJ, Chi HS, Yun SC, Lee KH.
    Leuk Res; 2009 Apr 01; 33(4):511-7. PubMed ID: 18819710
    [Abstract] [Full Text] [Related]

  • 8. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH.
    Leuk Res; 2006 Feb 01; 30(2):204-10. PubMed ID: 16055185
    [Abstract] [Full Text] [Related]

  • 9. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Feb 01; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 10. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun 01; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 11. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May 01; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 12. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL.
    Am J Hematol; 2008 Mar 01; 83(3):185-8. PubMed ID: 17899614
    [Abstract] [Full Text] [Related]

  • 13. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S, Mizoguchi H, Tomonaga M, Kanamaru A, Tsukagoshi S, Nakamura T, Ohashi Y, Yoshida S, Ohno R.
    Gan To Kagaku Ryoho; 1998 Dec 01; 25(14):2229-42. PubMed ID: 9881080
    [Abstract] [Full Text] [Related]

  • 14. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May 01; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 15. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
    Hiraoka A, Sampi K, Kuraishi Y, Takemoto Y, Okabe K, Tamura K, Ogawa M.
    Gan To Kagaku Ryoho; 1999 Jan 01; 26(1):93-9. PubMed ID: 9987504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
    Tauro S, Shankaranarayana P, Nitu-Whalley IC, Duncan N, Begum G, Craig JI, Marcus RE, Craddock CF, Mahendra P.
    Bone Marrow Transplant; 2003 Aug 01; 32(3):273-8. PubMed ID: 12858198
    [Abstract] [Full Text] [Related]

  • 18. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM.
    Cancer; 1999 Jan 15; 85(2):358-67. PubMed ID: 10023703
    [Abstract] [Full Text] [Related]

  • 19. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
    Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D.
    J Clin Oncol; 2005 Jun 20; 23(18):4110-6. PubMed ID: 15961759
    [Abstract] [Full Text] [Related]

  • 20. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 20; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.